Postmenopausal hormone use and the risk of nephrolithiasis: Results from the women's health initiative hormone therapy trials

Archives of Internal Medicine

Volumn 170, Issue 18, 2010, Pages 1678-1685

  Maalouf, Naim M ^a   Sato, Alicia H ^b   Welch, Brian J ^a,f   Howard, Barbara V ^c   Cochrane, Barbara B ^b,d   Sakhaee, Khashayar ^a   Robbins, John A ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ESTROGEN PLUS PROGESTIN; GESTAGEN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ESTROGEN THERAPY; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; CLINICAL TRIALS AS TOPIC; CONFIDENCE INTERVALS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYSTERECTOMY; INCIDENCE; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; NEPHROLITHIASIS; ODDS RATIO; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 77957961364     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.342     Document Type: Article

References (31)

1. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63(5):1817-1823.
2. Rule AD, Bergstralh EJ, Melton LJ III, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(4):804-811.
3. Pearle MS, Calhoun EA, Curhan GC; Urologic Diseases of America Project. Urologic diseases in America project: urolithiasis. J Urol. 2005;173(3):848-857.
4. Marshall V, White RH, De Saintonge MC, Tresidder GC, Blandy JP. The natural history of renal and ureteric calculi. Br J Urol. 1975;47(2):117-124.
5. Johnson CM, Wilson DM, O'Fallon WM, Malek RS, Kurland LT. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int. 1979;16(5):624-631.
6. Heller HJ, Sakhaee K, Moe OW, Pak CY. Etiological role of estrogen status in renal stone formation. J Urol. 2002;168(5):1923-1927.
7. Dey J, Creighton A, Lindberg JS, et al. Estrogen replacement increased the citrate and calcium excretion rates in postmenopausal women with recurrent urolithiasis. J Urol. 2002;167(1):169-171. (Pubitemid 34024524)
8. Mattix Kramer HJ, Grodstein F, Stampfer MJ, Curhan GC. Menopause and postmenopausal hormone use and risk of incident kidney stones. J Am Soc Nephrol. 2003;14(5):1272-1277. (Pubitemid 36514667)
9. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61-109.
10. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(9)(suppl):S78-S86. (Pubitemid 37324177)
11. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
12. Anderson GL, Limacher M, Assaf AR, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
13. Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006;367(9507):333-344.
14. Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J. 1973;1(5851):449-451.
15. Adamopoulos D, Vlassopoulos C, Seitanides B, Contoyiannis P, Vassilopoulos P. The relationship of sex steroids to uric acid levels in plasma and urine. Acta Endocrinol (Copenh). 1977;85(1):198-208. (Pubitemid 8087786)
16. Pak CY, Arnold LH. Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc Soc Exp Biol Med. 1975;149(4):930-932.
17. Coe FL, Lawton RL, Goldstein RB, Tembe V. Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc Soc Exp Biol Med. 1975;149(4):926-929.
18. Gallagher JC, Riggs BL, DeLuca HF. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1980;51(6):1359-1364. (Pubitemid 11199628)
19. Hassager C, Colwell A, Assiri AM, Eastell R, Russell RG, Christiansen C. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin Endocrinol (Oxf ). 1992;37(1):45-50.
20. McKane WR, Khosla S, Burritt MF, et al. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause - a clinical research center study. J Clin Endocrinol Metab. 1995;80(12):3458- 3464.
21. Kluft C, Meijer P, LaGuardia KD, Fisher AC. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception. 2008;77(2):77-83.
22. Stapleton AM, Seymour AE, Brennan JS, Doyle IR, Marshall VR, Ryall RL. Immunohistochemical distribution and quantification of crystal matrix protein. Kidney Int. 1993;44(4):817-824. (Pubitemid 23290523)
23. Lieske JC, Peña de la Vega LS, Slezak JM, et al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 2006;69(4):760-764.
24. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293(4):455-462.
25. Hreshchyshyn MM, Hopkins A, Zylstra S, Anbar M. Effects of natural menopause, hysterectomy, and oophorectomy on lumbar spine and femoral neck bone densities. Obstet Gynecol. 1988;72(4):631-638.
26. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1):47-53.
27. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004;140(3):184-188.
28. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-1674.
29. Chlebowski RT, Kuller LH, Prentice RL, et al; WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573-587.
30. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993;328(12):833-838.
31. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med. 1997;126(7):497-504. (Pubitemid 27143627)